A team of Vanderbilt researchers mapped out the genomic landscape of a metastatic malignant proliferating tricholemmal tumor and identified a targeted treatment for this very rare cancer.
About a decade ago, at the beginning of his career in academic medicine, Brian Engelhardt, MD, MSCI, noticed that many of his patients receiving a stem cell transplant for their blood cancer ended up with diabetes.
